Home LiteratureArticle Details
PMID: 9500957 Published · ppublish English Journal Article

Combined treatment of acute EAE in Lewis rats with TNF-binding protein and interleukin-1 receptor antagonist.

Experimental neurology ·Vol. 149 ·No. 2 ·1998-02-00 ·Pages 455-63

Wiemann B, Van GY, Danilenko DM, Yan Q, Matheson C, Munyakazi L, Ogenstad S, Starnes CO

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a term given to describe a collection of animal models representing the human disease multiple sclerosis (MS). Although not fully understood, the involvement of cytokines and the immune system in either EAE or human MS is well established. Past efforts have shown that inhibition of proinflammatory cytokines tumor necrosis factor (TNF-alpha) or interleukin-1 (IL-1) result in amelioration of acute EAE in Lewis rats. The present study examined this model for the effect of concomitant inhibition of both TNF-alpha and IL-1, which resulted in a modest but significant therapeutic effect that was superior to inhibition of either single agent alone with respect to four of the five variables used to follow the progression of disease in this model, i.e., clinical severity, frequency of disease, loss of body weight, and day of onset. These results are in accordance with the idea that combination treatments are likely to prove superior to single agent therapy in the treatment of autoimmune inflammatory disease.

MeSH Terms
Animals Brain/immunology,pathology Dimerization Drug Administration Schedule Drug Therapy, Combination Encephalomyelitis, Autoimmune, Experimental/pathology,physiopathology,therapy Female Humans Injections, Intravenous Injections, Subcutaneous Integrin alpha4beta1 Integrins/biosynthesis Intercellular Adhesion Molecule-1/biosynthesis Interleukin 1 Receptor Antagonist Protein Interleukin-1/antagonists & inhibitors Lymphocyte Function-Associated Antigen-1/biosynthesis Polyethylene Glycols Rats Rats, Inbred Lew Receptors, Lymphocyte Homing/biosynthesis Receptors, Tumor Necrosis Factor/administration & dosage,therapeutic use Receptors, Very Late Antigen/immunology Sialoglycoproteins/administration & dosage,therapeutic use Spinal Cord/immunology,pathology Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemicals
IL1RN protein, human Integrin alpha4beta1 Integrins Interleukin 1 Receptor Antagonist Protein Interleukin-1 Lymphocyte Function-Associated Antigen-1 Receptors, Lymphocyte Homing Receptors, Tumor Necrosis Factor Receptors, Very Late Antigen Sialoglycoproteins Tumor Necrosis Factor-alpha Intercellular Adhesion Molecule-1 Polyethylene Glycols
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Wiemann B
Department of Pharmacology, Amgen, Inc., Thousand Oaks, California 91320-1789, USA.
Van G Y
Danilenko D M
Yan Q
Matheson C
Munyakazi L
Ogenstad S
Starnes C O
Article Info
Journal
Experimental neurology
Abbr.
Exp Neurol
ISSN
0014-4886
Published
1998-02-00
Pages
455-63
Language
English
Region
United States
NLM ID
0370712
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com